Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Dual-expression-site fowl adenovirus 4 (FAdV-4) with high viral titer: a promising viral vector for multivalent poultry vaccines.

Created on 14 Aug 2026

Authors

Zhihui Tang, Wenjian Liu, Biao Xu, Dengfei Feng, Shuhui Liu, Wentao Fan, Suquan Song, Liping Yan

Published in

Veterinary research. Volume 57. Issue 1. Aug 13, 2026. Epub Aug 13, 2026.

Abstract

Fowl adenovirus serotype 4 (FAdV-4) is a nonenveloped double-stranded DNA virus with a 43-45 kb genome, making it a promising viral vector for developing multivalent poultry vaccines. However, limited genomic studies have hindered the design of strategies for generating recombinant FAdV-4 capable of expressing multiple foreign proteins while maintaining high viral titers. In this study, three deletion mutants (rD14AB, rD2042, rD19A) were generated to assess their roles in viral replication and pathogenicity. Only rD2042 showed impaired replication and virulence compared with wild-type FAdV-4. Foreign gene expression assays demonstrated that the D14AB site had a maximum insertion capacity of 2349 bp, and an SV40 poly(A) signal was required for efficient protein expression and viral propagation at this locus. In contrast, the D19A site tolerated insertions of up to 1257 bp in the absence of this signal. Using the insertion strategy optimized for wild-type CH_JS_2017, we modified the previously reported nonpathogenic rON1 strain (harboring the Hexon gene from the attenuated ON1 strain) to co-express mCherry, eGFP, and mTagBFP2 at the two independent sites. SPF chicken trials verified the safety of the engineered virus at immunization age and the genetic stability of exogenous genes. The recombinant virus maintained wild-type-comparable titers while carrying 3606 bp of total foreign sequences, highlighting its dual-site advantage and potential as a multivalent poultry vaccine vector.

PMID:
42596021
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement